A carregar...
Bispecific Antibodies: A Smart Arsenal for Cancer Immunotherapies
Following the clinical success of cancer immunotherapies such as immune checkpoint inhibitors blocking B7/CTLA-4 or PD-1/PD-L1 signaling and ongoing numerous combination therapies in the clinic,3 bispecific antibodies (BsAbs) are now emerging as a growing class of immunotherapies with the potential...
Na minha lista:
| Publicado no: | Vaccines (Basel) |
|---|---|
| Main Authors: | , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
MDPI
2021
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8310217/ https://ncbi.nlm.nih.gov/pubmed/34358141 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/vaccines9070724 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|